Description du projet
Une analyse efficace des données pour la recherche sur les maladies
La variété des données constitue l’un des plus grands obstacles de la recherche sur les maladies lorsqu’il s’agit d’étudier les mécanismes sous-jacents ou de hiérarchiser les cibles pour de nouveaux traitements. Cette diversité se traduit par un rendement et une qualité médiocres. La société technologique allemande knowing01 a mis au point un logiciel en tant que service qui permet à l’utilisateur de connecter et d’explorer les données de l’OMIC indépendamment du type de données biologiques. Cette approche innovante de traduction des données basée sur les graphes de connaissances permettra aux scientifiques d’effectuer des analyses sur plusieurs types de données et de comparer différents ensembles dans leur contexte biologique. Le projet BInno2scalek01, financé par l’UE, procédera à une évaluation critique de cette technologie. Il exploitera la position de marché de niche de la technologie et fera progresser l’infrastructure et les technologies liées aux bases de données. BInno2scalek01 bénéficiera de la subvention Women TechEU.
Objectif
Aren’t we expecting from disease research that all available data is being used? Yes! Yet one of the biggest hurdles is the data variety when to studying underlying mechanisms or prioritizing targets for novel treatments. Ultimately stalling projects and resulting in low output and quality. knowing01 GmbH is a deep tech software company founded in 2020 in Munich, Germany that gives Life Scientists full control of all their research data. Dr. Nikola Müller (founder and CEO) has spearheaded the project since 2014, when the idea budded during her academic research at Helmholtz Munich. The knowing01 solution is a software-as-a-service (SaaS) suite that allows the user to connect and explore omics data no matter their biodata type. Our innovative knowledge-graph based translation approach empowers scientists to run analyses across data types and compare different sets in their biological context. We additionally offer on client premise, licensed software. Our next challenging milestone is to scale a) by innovating the business and b) by having a critical assessment of the technology. We aim to exploit our niche market position. We are specifically aiming to be attractive to key partners that offer our together with their own services. We need scale our infrastructure and database-related technologies alongside with the business. Only both will allow us to future-proof our business paving the way for a sustainable business. Dr. Nikola Müller will profit from being part of the Women Leadership Program by sharpening negotiation skills, learning how to improve public visibility and finally, getting into potent female-friendly investor networks. Compared to classical IT, biotech or digital health companies, our offering opens a yet unexplored niche, which is why we will enormously profit from the Women TechEU grant. The non-dilutive funding will be critical of us being able to support the scale-developments to be able to move our business forward.
Champ scientifique
Programme(s)
- HORIZON.3.2 - European innovation ecosystems Main Programme
Régime de financement
HORIZON-AG-LS - HORIZON Lump Sum GrantCoordinateur
81243 MUNCHEN
Allemagne
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.